What are the differences between Dayvigo (lemborexant) and Belsomra (suvorexant)?

Dayvigo vs Belsomra: Key Differences

Both Dayvigo (lemborexant) and Belsomra (suvorexant) are dual orexin receptor antagonists (DORAs) approved for insomnia, but lemborexant demonstrates superior efficacy for sleep onset and appears to have a more favorable side effect profile, particularly regarding next-day somnolence.

Mechanism of Action

Both medications work through the same fundamental mechanism—blocking orexin receptors (OX1R and OX2R) to suppress wake drive. However, there are subtle pharmacological differences:

• Lemborexant (Dayvigo): Binds to OX1R and OX2R with IC50 values of 6.1 nM and 2.6 nM respectively, showing slightly stronger affinity for OX2R 1
• Suvorexant (Belsomra): Also blocks both receptors but with different binding characteristics that may explain clinical differences 2

The stronger OX2R inhibition by lemborexant likely explains its more potent effect on sleep onset observed in clinical practice 3.

Clinical Efficacy Differences

Sleep Onset (Initial Insomnia)

Lemborexant is significantly more effective for sleep onset, particularly on the first night of treatment:

• Network meta-analysis showed lemborexant 10 mg had the largest effect size for subjective time to sleep onset (sTSO) at week 1 compared to all other treatments including suvorexant (standardized mean difference: -0.51 vs -0.21 for suvorexant) 4
• Real-world data confirms lemborexant produces significantly longer sleep duration on day 1 of treatment (5.93 vs 5.10 hours, p=0.017) 3
• Discontinuation due to lack of efficacy was significantly lower with lemborexant (4.9%) versus suvorexant (7.1%), odds ratio 0.63 5

Sleep Maintenance

Both medications are effective for sleep maintenance insomnia, with AASM guidelines providing weak recommendations for both 2. However:

• Lemborexant 10 mg showed superior effect size for subjective total sleep time (-0.58) and wake after sleep onset (-0.42) compared to suvorexant 20/15 mg (-0.34 and -0.18 respectively) 4
• Patients switching from suvorexant to lemborexant specifically for difficulty initiating sleep showed significant improvement (OR=0.036, p=0.008) 6

Guideline Recommendations

The 2017 AASM guidelines provide weak recommendations for both medications 2:

• Suvorexant: Suggested for sleep maintenance insomnia (based on 10,15/20, and 20 mg doses)
• Lemborexant: Not included in 2017 guidelines as it wasn't yet available

The 2020 VA/DOD guidelines state there is insufficient evidence to recommend for or against suvorexant for chronic insomnia disorder 7, reflecting the conservative nature of guideline development despite available efficacy data.

Safety and Tolerability Profile

Somnolence Risk

Lemborexant appears to cause less problematic somnolence despite being more effective:

• Suvorexant showed dose-dependent increases in daytime somnolence (20 mg: 4.9%; 15/20 mg: 5.1-8.4%) 2
• Lemborexant 10 mg was associated with somnolence but at rates that may be more tolerable in clinical practice 4
• Real-world data showed lemborexant had lower incidence of side effects requiring discontinuation (2.9% vs 12.5%, though not statistically significant p=0.10) 8

Falls Risk

Limited data suggests no significant difference in fall risk between the two medications (0% vs 5.3%, p=0.248), though this requires larger studies 3.

Abuse Potential

Both are Schedule IV controlled substances. Lemborexant produced similar subjective responses to suvorexant in abuse liability studies, meaning both have comparable low abuse potential 1.

Practical Dosing Considerations

Lemborexant (Dayvigo)

• Available as 5 mg and 10 mg tablets
• Starting dose: 5 mg, may increase to 10 mg
• Take immediately before bed with ≥7 hours remaining for sleep
• Food delays absorption by 2 hours and decreases Cmax by 23% 1

Suvorexant (Belsomra)

• Doses studied: 10,15/20, and 20 mg
• FDA-approved dosing based on clinical trials 2
• Similar timing requirements

Drug Interactions

Both medications are primarily metabolized by CYP3A4 1. Key considerations:

• Strong CYP3A4 inhibitors: Reduce doses or avoid
• Moderate CYP3A4 inhibitors: Use lower doses
• Alcohol: Both produce additive CNS depression; lemborexant specifically showed greater negative impact on postural stability and memory when combined with alcohol 1

Special Populations

Respiratory Compromise

• Lemborexant has not been studied in COPD patients with FEV1 <30% of predicted; clinically meaningful respiratory effects cannot be excluded 1
• Similar caution applies to suvorexant based on class effects

Elderly Patients

Both require dose adjustments in elderly or debilitated patients due to increased sensitivity to CNS effects.

Clinical Algorithm for Selection

Choose Lemborexant when:

• Sleep onset insomnia is the primary complaint
• Patient has failed suvorexant due to lack of efficacy
• Rapid onset of action on first night is desired
• Patient is concerned about next-day effects

Choose Suvorexant when:

• Sleep maintenance is the primary issue without significant sleep onset problems
• Lemborexant is not available or not covered by insurance
• Patient has successfully used it previously

Switch from Suvorexant to Lemborexant if:

• Persistent difficulty initiating sleep after 3 months of suvorexant 6
• Intolerable side effects on suvorexant
• Inadequate efficacy despite appropriate dosing

Common Pitfalls

1. Don't assume equivalent efficacy: Despite being in the same class, lemborexant shows superior sleep onset effects in head-to-head comparisons 4
2. Don't ignore food effects: Taking lemborexant with food significantly delays and reduces absorption 1
3. Don't use simple suspension method for Belsomra: Unlike lemborexant, suvorexant tablets do not disintegrate properly for administration via feeding tube 9
4. Don't exceed recommended doses: Higher doses of suvorexant (>20 mg) show significantly increased somnolence without proportional efficacy gains 2